Drugs in ATC Class C02DB

Up to Top Level ATC Classes

Up to C - Cardiovascular system

Up to C02 - ANTIHYPERTENSIVES

Up to C02D - ARTERIOLAR SMOOTH MUSCLE, AGENTS ACTING ON

Drugs in ATC Class: C02DB - Hydrazinophthalazine derivatives

Tradename	Generic Name
APRESAZIDE	hydralazine hydrochloride; hydrochlorothiazide
APRESOLINE	hydralazine hydrochloride
DRALZINE	hydralazine hydrochloride
HYDRALAZINE HYDROCHLORIDE	hydralazine hydrochloride

C02DB Market Analysis and Financial Projection

The Hydrazinophthalazine derivatives class (ATC C02DB), primarily represented by hydralazine hydrochloride, demonstrates a complex interplay of market growth, declining therapeutic use, and ongoing pharmaceutical innovation. Here's a comprehensive analysis:

Market Dynamics

• Global Market Valuation: The hydralazine hydrochloride market reached $500M in 2025, projected to grow at 5% CAGR through 2033[4]. North America and Europe dominate, while Asia-Pacific shows the fastest growth due to healthcare expansion in India/China[4].
• Key Drivers:
  • Rising hypertension prevalence (2.4B cases globally by 2025)[1]
  • Cost-effectiveness of generic formulations (28 branded versions available)[1]
  • High-purity demand (≥99.9% grades growing at 6.8% CAGR)[4]
• Market Constraints:
  • Competition from newer antihypertensives (C09-class drugs grew 28.5% vs C02-class decline)[6]
  • Raw material price volatility and complex synthesis[4]

Market Segment	2025 Share	Growth Driver
Tablet Formulations	68%	Patient compliance
Parenteral Preparations	22%	Emergency care needs
Combination Therapies	10%	Heart failure protocols[7]

Patent Landscape

• Key Innovations:
  • Stabilization methods: US7,989,452 (alkane-based purification)[2] and US6,825,196 (N-protecting groups)[15]
  • Combination therapy: US4,868,179 (hydralazine + isosorbide dinitrate)[7]
• Competitive IP Activity:
  • 1,754 patent applications filed globally[1]
  • 15 active Drug Master Files[1]
  • Major assignees: Novartis (28 brands), Teva, Mylan, Sun Pharma[1][12]

Emerging Trends:

1. API purification technologies reducing N-nitroso impurities[2]
2. Delayed-release formulations for sustained hypertension control
3. Fixed-dose combinations with digitalis glycosides[9]

Therapeutic Utilization Patterns

• Approved Indications:
  • Hypertension (I10 ICD-10)[9]
  • Heart failure adjunct therapy[13]
  • Pre-eclampsia management[11]
• Prescription Trends:
  • Only 0.7% of EU heart failure patients receive guideline-recommended hydralazine combinations[13]
  • Consumption declined 11.1% in C02-class drugs vs 36.5% growth in C09-class[6]

Dosing Considerations:

• Oral DDD: 100mg daily[5]
• Parenteral: 10-40mg IV every 4-6 hours[11]
• Ethnic-specific efficacy: 39% mortality reduction in African-Americans[7]

Competitive Landscape

• Supply Chain:
  • 40 finished product suppliers
  • 118 API vendors globally[1]
• Regulatory Developments:
  • 125 NDAs approved[1]
  • 65 active clinical trials (Phase III trials in Iran/Canada)[1]
• Cost Factors:
  • Generic price erosion (15-20% since 2020)
  • API production cost: $12-18/kg[12]

Strategic Recommendations

1. Patent Extension: Develop sustained-release formulations to counter generic competition
2. Market Expansion: Target emerging economies through WHO prequalification programs
3. Combo Therapy Push: Leverage V-HeFT trial data to increase HFrEF adoption[7][13]
4. Manufacturing Innovation: Implement continuous flow synthesis (current yield: 72-78%)[12]

"The stability challenges in hydralazine formulations have driven 64% of recent patents, reflecting unmet needs in tropical climate distribution"[2][15].

While facing pressure from newer drug classes, Hydrazinophthalazine derivatives retain niche value in resistant hypertension and ethnicity-specific therapies. Success requires balancing generic competition through formulation innovation and targeted clinical education.

References

1. https://www.drugpatentwatch.com/p/generic/hydralazine+hydrochloride
2. https://patentimages.storage.googleapis.com/c8/e0/d6/5d9d7337be9306/US7989452.pdf
3. https://www.knowmade.com/technology-news/semiconductor-news/semiconductor-packaging-news/advanced-semiconductor-packaging-leading-patent-owners-and-new-entrants/
4. https://www.promarketreports.com/reports/hydralazine-hcl-54492
5. https://atcddd.fhi.no/atc_ddd_index/?code=C02DB02
6. https://pmc.ncbi.nlm.nih.gov/articles/PMC8673596/
7. https://www.sysrevpharm.org/articles/hydralazine-and-isosorbide-dinitrate-an-analytical-review.pdf
8. https://www.patentstyret.no/en/media/documents/reports/carbon-capture-technology.pdf
9. https://www.pharmakb.com/drug-report/dihydralazine
10. https://fhi.brage.unit.no/fhi-xmlui/bitstream/handle/11250/2984467/Berg-2018-Res.pdf?sequence=1
11. https://go.drugbank.com/drugs/DB01275
12. https://www.pharmacompass.com/active-pharmaceutical-ingredients/hidralazin
13. https://pmc.ncbi.nlm.nih.gov/articles/PMC6487721/
14. https://journals.plos.org/plosone/article/file?id=10.1371%2Fjournal.pone.0259467&type=printable
15. https://patents.google.com/patent/US6825196B2/en
16. https://go.drugbank.com/categories/DBCAT002524